

Emily Han-Chung Hsiue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/422421/publications.pdf>

Version: 2024-02-01

167
papers

8,326
citations

61984

43
h-index

53230

85
g-index

169
all docs

169
docs citations

169
times ranked

11477
citing authors

#	ARTICLE	IF	CITATIONS
1	Prescription Opioid Analgesics Commonly Unused After Surgery. <i>JAMA Surgery</i> , 2017, 152, 1066.	4.3	688
2	National Trends in Ambulatory Oral Anticoagulant Use. <i>American Journal of Medicine</i> , 2015, 128, 1300-1305.e2.	1.5	513
3	Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. <i>JAMA Internal Medicine</i> , 2016, 176, 473.	5.1	477
4	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	341
5	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. <i>JAMA Network Open</i> , 2020, 3, e2021476.	5.9	332
6	Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. <i>BMJ, The</i> , 2015, 350, h1857-h1857.	6.0	291
7	Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. <i>JAMA Internal Medicine</i> , 2018, 178, 1451.	5.1	219
8	Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. <i>JAMA Internal Medicine</i> , 2015, 175, 1642.	5.1	207
9	Targeting a neoantigen derived from a common TP53 mutation. <i>Science</i> , 2021, 371, .	12.6	194
10	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. <i>Pharmacotherapy</i> , 2018, 38, 907-920.	2.6	160
11	Evaluation of Aducanumab for Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1717.	7.4	152
12	Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. <i>American Journal of Emergency Medicine</i> , 2014, 32, 421-431.	1.6	128
13	The availability of pharmacies in the United States: 2007-2015. <i>PLoS ONE</i> , 2017, 12, e0183172.	2.5	127
14	Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. <i>BMJ, The</i> , 2015, 350, h1585-h1585.	6.0	126
15	Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function. <i>JAMA Internal Medicine</i> , 2018, 178, 903.	5.1	126
16	Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. <i>JAMA Psychiatry</i> , 2014, 71, 1006.	11.0	120
17	Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2018, 178, 1190.	5.1	120
18	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e213071.	5.9	113

#	ARTICLE	IF	CITATIONS
19	Bispecific antibodies targeting mutant <i>RAS</i> neoantigens. <i>Science Immunology</i> , 2021, 6, .	11.9	106
20	Revisiting FDA Approval of Aducanumab. <i>New England Journal of Medicine</i> , 2021, 385, 769-771.	27.0	104
21	Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. <i>JAMA Network Open</i> , 2018, 1, e183044.	5.9	98
22	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2017, 130, 293-305.	1.5	96
23	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. <i>Lancet Rheumatology</i> , The, 2022, 4, e33-e41.	3.9	96
24	Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis. <i>Drug and Alcohol Dependence</i> , 2016, 165, 1-8.	3.2	95
25	Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 943-956.	11.4	92
26	Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. <i>Addiction</i> , 2017, 112, 1784-1796.	3.3	91
27	Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1159.	7.4	91
28	Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 637-645.	1.9	85
29	Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion. <i>JAMA Network Open</i> , 2018, 1, e181588.	5.9	82
30	Rethinking Opioid Prescribing to Protect Patient Safety and Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1865.	7.4	79
31	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021, 2, 487-497.	13.2	79
32	Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 157.	1.8	75
33	Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011-2016. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108416.	3.2	74
34	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	72
35	Effect of a pill mill law on opioid prescribing and utilization: The case of Texas. <i>Drug and Alcohol Dependence</i> , 2016, 159, 190-197.	3.2	71
36	Ensuring Access to Medications in the US During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 31.	7.4	66

#	ARTICLE	IF	CITATIONS
37	Opioid Oversupply After Joint and Spine Surgery: A Prospective Cohort Study. <i>Anesthesia and Analgesia</i> , 2019, 128, 358-364.	2.2	61
38	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0234065.	2.5	59
39	Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017. <i>JAMA Network Open</i> , 2019, 2, e195388.	5.9	58
40	Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults. <i>Drugs and Aging</i> , 2018, 35, 735-750.	2.7	54
41	Fewer Pharmacies In Black And Hispanic/Latino Neighborhoods Compared With White Or Diverse Neighborhoods, 2007-15. <i>Health Affairs</i> , 2021, 40, 802-811.	5.2	54
42	Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). <i>Addiction</i> , 2017, 112, 311-319.	3.3	53
43	Association Between Chronic Use of Immunosuppressive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System. <i>Clinical Infectious Diseases</i> , 2021, 73, e4124-e4130.	5.8	51
44	Prevalence of Dietary Supplement Use in US Children and Adolescents, 2003-2014. <i>JAMA Pediatrics</i> , 2018, 172, 780.	6.2	46
45	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , 2021, 44, 1564-1572.	8.6	43
46	Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 286-293.	2.6	42
47	Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. <i>Addictive Behaviors</i> , 2014, 39, 829-836.	3.0	41
48	Quality of Prescribing by Physicians, Nurse Practitioners, and Physician Assistants in the United States. <i>Pharmacotherapy</i> , 2018, 38, 417-427.	2.6	41
49	Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e031850.	1.9	41
50	Prescription drug monitoring program design and function: A qualitative analysis. <i>Drug and Alcohol Dependence</i> , 2017, 180, 395-400.	3.2	40
51	Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 4-6.	27.0	40
52	Direct Detection and Quantification of Neoantigens. <i>Cancer Immunology Research</i> , 2019, 7, 1748-1754.	3.4	40
53	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	39
54	Racial disparities in reaching the renal transplant waitlist: is geography as important as race?. <i>Clinical Transplantation</i> , 2015, 29, 531-538.	1.6	37

#	ARTICLE	IF	CITATIONS
55	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open, 2018, 1, e180235.	5.9	37
56	Trends in Oncology Clinical Trials Launched Before and During the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2036353.	5.9	37
57	Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. JAMA Internal Medicine, 2021, 181, 562.	5.1	37
58	Financial Conflicts of Interest and the Centers for Disease Control and Prevention's 2016 Guideline for Prescribing Opioids for Chronic Pain. JAMA Internal Medicine, 2017, 177, 427.	5.1	36
59	Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. Journal of Rheumatology, 2021, 48, 385-393.	2.0	36
60	Automatable algorithms to identify nonmedical opioid use using electronic data: a systematic review. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 1204-1210.	4.4	33
61	Evaluation of Flibanserin. JAMA - Journal of the American Medical Association, 2015, 314, 869.	7.4	31
62	More States Should Regulate Pain Management Clinics to Promote Public Health. American Journal of Public Health, 2017, 107, 240-243.	2.7	31
63	Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS ONE, 2018, 13, e0195012.	2.5	30
64	Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA - Journal of the American Medical Association, 2019, 321, 676.	7.4	30
65	TCR \hat{I}^2 chain-directed bispecific antibodies for the treatment of T cell cancers. Science Translational Medicine, 2021, 13, .	12.4	30
66	Impact of Florida's prescription drug monitoring program and pill mill law on high-risk patients: A comparative interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 422-429.	1.9	29
67	Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 2021, 97, e1266-e1275.	1.1	29
68	Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3969-3976.	3.8	28
69	Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 40-46.	5.6	27
70	Optimizing opioid prescribing and pain treatment for surgery: Review and conceptual framework. American Journal of Health-System Pharmacy, 2019, 76, 1403-1412.	1.0	27
71	Digitalis Use in Contemporary Clinical Practice. JAMA Internal Medicine, 2014, 174, 151.	5.1	26
72	Prescription Drug Abuse. JAMA Internal Medicine, 2015, 175, 302.	5.1	26

#	ARTICLE	IF	CITATIONS
73	High-Risk Prescription Opioid Use Among People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 283-290.	2.1	26
74	Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2020, 180, 301.	5.1	25
75	Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. <i>JAMA Internal Medicine</i> , 2021, 181, 52.	5.1	25
76	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. <i>JAMA Network Open</i> , 2020, 3, e2023677.	5.9	24
77	Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 428-430.	3.9	23
78	Effects of State Opioid Prescribing Laws on Use of Opioid and Other Pain Treatments Among Commercially Insured U.S. Adults. <i>Annals of Internal Medicine</i> , 2022, 175, 617-627.	3.9	23
79	Non-buprenorphine opioid utilization among patients using buprenorphine. <i>Addiction</i> , 2017, 112, 1045-1053.	3.3	22
80	Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers. <i>Addiction</i> , 2018, 113, 677-686.	3.3	22
81	Perceived Unintended Consequences of Prescription Drug Monitoring Programs. <i>Substance Use and Misuse</i> , 2019, 54, 345-349.	1.4	21
82	Implementation and enforcement of state opioid prescribing laws. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108107.	3.2	21
83	Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108811.	3.2	20
84	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. <i>Oncologist</i> , 2017, 22, 843-849.	3.7	19
85	Reducing High-Dose Opioid Prescribing: State-Level Morphine Equivalent Daily Dose Policies, 2007-2017. <i>Pain Medicine</i> , 2020, 21, 308-316.	1.9	19
86	Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation. <i>Nephrology</i> , 2019, 24, 234-244.	1.6	19
87	Assessment of Pharmacy Closures in the United States From 2009 Through 2015. <i>JAMA Internal Medicine</i> , 2020, 180, 157.	5.1	19
88	Making the Case for Accelerated Withdrawal of Aducanumab. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1003-1007.	2.6	19
89	Association of new opioid continuation with surgical specialty and type in the United States. <i>American Journal of Surgery</i> , 2019, 218, 818-827.	1.8	18
90	Association Between Lithium Use and Risk of Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e139-e145.	2.2	18

#	ARTICLE	IF	CITATIONS
91	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	2.5	17
92	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nature Communications, 2021, 12, 5271.	12.8	17
93	National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012. PLoS ONE, 2015, 10, e0119292.	2.5	16
94	Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists. American Journal of Emergency Medicine, 2017, 35, 1414-1419.	1.6	16
95	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Review of Respiratory Medicine, 2017, 11, 51-55.	2.5	16
96	Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States. Journal of the American Medical Directors Association, 2017, 18, 138-144.	2.5	16
97	Opportunities of circulating tumor DNA in lung cancer. Cancer Treatment Reviews, 2019, 78, 31-41.	7.7	16
98	Trends in Opioid Prescribing Among Hemodialysis Patients, 2007-2014. American Journal of Nephrology, 2019, 49, 20-31.	3.1	16
99	Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. JAMA Network Open, 2021, 4, e2128782.	5.9	16
100	Medicaid trends in prescription opioid and non-opioid use by HIV status. Drug and Alcohol Dependence, 2019, 197, 141-148.	3.2	15
101	Trends in Exposure to Televised Prescription Drug Advertising, 2003-2011. American Journal of Preventive Medicine, 2015, 48, 575-579.	3.0	14
102	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	2.4	14
103	Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics, 2018, 40, 95-102.e2.	2.5	14
104	The Influence of Surrogate Decision Makers on Clinical Decision Making for Critically Ill Adults. Journal of Intensive Care Medicine, 2015, 30, 278-285.	2.8	13
105	Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009. Nicotine and Tobacco Research, 2016, 18, 1180-1187.	2.6	13
106	Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis. International Journal of Gynecological Pathology, 2017, 36, 562-567.	1.4	13
107	Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: disproportionality analysis among high-risk patients. Pharmacoepidemiology and Drug Safety, 2018, 27, 660-667.	1.9	12
108	Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016. Clinical Trials, 2019, 16, 329-333.	1.6	12

#	ARTICLE	IF	CITATIONS
109	Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017. <i>Clinical Trials</i> , 2020, 17, 119-125.	1.6	12
110	Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1685-1694.	2.6	12
111	Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. <i>JAMA Network Open</i> , 2021, 4, e2138807.	5.9	12
112	Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0211820.	2.5	11
113	Clean indoor air laws, cigarette excise taxes, and smoking: Results from the current population survey-tobacco use supplement, 2003-2011. <i>Preventive Medicine</i> , 2019, 126, 105744.	3.4	10
114	Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016. <i>Pharmacotherapy</i> , 2022, 42, 375-386.	2.6	10
115	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2123406119.	7.1	10
116	Prescription drug monitoring programs: Assessing the association between best practices and opioid use in Medicare. <i>Health Services Research</i> , 2019, 54, 1045-1054.	2.0	9
117	Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products. <i>Value in Health</i> , 2020, 23, 1599-1605.	0.3	9
118	Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. <i>Clinical and Translational Science</i> , 2021, 14, 153-162.	3.1	9
119	Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1843-1850.	4.4	9
120	Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1282-1290.	0.9	9
121	Using Certification to Promote Uptake of Real-World Evidence by Payers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 191-196.	0.9	8
122	Increasing uptake of comparative effectiveness and patient-centered outcomes research among stakeholders: insights from conference discussion. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 181-191.	1.4	8
123	Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1066-1073.	2.6	8
124	Quality of Preventive and Chronic Illness Care for Insured Adults With Opioid Use Disorder. <i>JAMA Network Open</i> , 2021, 4, e214925.	5.9	8
125	Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. <i>Pharmacotherapy</i> , 2022, 42, 567-579.	2.6	8
126	Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. <i>Journal of Nephrology</i> , 2017, 30, 831-839.	2.0	7

#	ARTICLE	IF	CITATIONS
127	The Value of U.S. Pharmacopeial Standards: A Review of the Literature. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2611-2617.	3.3	7
128	Characteristics of Copayment Offsets for Prescription Drugs in the United States. <i>JAMA Internal Medicine</i> , 2021, 181, 758.	5.1	7
129	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. <i>Addiction</i> , 2022, 117, 969-976.	3.3	7
130	Family caregivers' facilitation of daily adult prescription medication use. <i>Patient Education and Counseling</i> , 2018, 101, 908-916.	2.2	6
131	Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 995-1004.	1.7	6
132	Digit Preference in Office Blood Pressure Measurements, United States 2015-2019. <i>American Journal of Hypertension</i> , 2021, 34, 521-530.	2.0	6
133	Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease. <i>PLoS ONE</i> , 2020, 15, e0240141.	2.5	6
134	Branded prescription drug spending: a framework to evaluate policy options. <i>Journal of Pharmaceutical Policy and Practice</i> , 2017, 10, 31.	2.4	5
135	Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 752-758.	1.6	5
136	Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 299.	7.4	5
137	Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e200274.	5.9	5
138	Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. <i>Medical Care</i> , 2021, 59, 393-401.	2.4	5
139	Predictors of new persistent opioid use after benign hysterectomy in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 68.e1-68.e24.	1.3	5
140	Cigarette excise taxes, clean indoor air laws, and use of smoking cessation treatments: A mediation analysis. <i>Preventive Medicine</i> , 2020, 136, 106098.	3.4	4
141	Tobacco control policies and smoking cessation treatment utilization: A moderated mediation analysis. <i>PLoS ONE</i> , 2021, 16, e0241512.	2.5	4
142	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. <i>JAMA Oncology</i> , 2021, 7, 1720-1721.	7.1	4
143	Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder. <i>Medical Care</i> , 2019, 57, 667-672.	2.4	3
144	High-dose opioid utilization and mortality among individuals initiating hemodialysis. <i>BMC Nephrology</i> , 2021, 22, 65.	1.8	3

#	ARTICLE	IF	CITATIONS
145	More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 113-125.	5.0	3
146	Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 914-921.	1.6	3
147	Valid-NEO: A Multi-Omics Platform for Neoantigen Detection and Quantification from Limited Clinical Samples. <i>Cancers</i> , 2022, 14, 1243.	3.7	3
148	Use of Prescription Medications With Cardiovascular Adverse Effects Among Older Adults in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	3
149	Cardiovascular risks associated with clarithromycin. <i>BMJ, The</i> , 2016, 352, i23.	6.0	2
150	Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. <i>PLoS ONE</i> , 2019, 14, e0225109.	2.5	2
151	Estimating the prevalence of and characteristics associated with prescription opioid diversion among a clinic population living with HIV: Indirect and direct questioning techniques. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108398.	3.2	2
152	Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. <i>Psychiatric Services</i> , 2021, 72, 77-80.	2.0	2
153	Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 16637.	3.3	2
154	Opioid Prescriptions After Total Joint Arthroplasty. <i>Journal of Surgical Orthopaedic Advances</i> , 2018, 27, 231-236.	0.1	2
155	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 72-75.	0.2	1
156	State Variation in Chronic Opioid Use in Long-Term Care Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2593-2599.e4.	2.5	1
157	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. <i>American Journal on Addictions</i> , 2014, 24, n/a-n/a.	1.4	1
158	Failure to fill a first prescription of a new medication is common in primary care settings. <i>Evidence-Based Medicine</i> , 2014, 19, 196-196.	0.6	0
159	Capsule Commentary on Faerber et al., Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs. <i>Journal of General Internal Medicine</i> , 2014, 29, 180-180.	2.6	0
160	Editorialistsâ€™ reply to Blake. <i>BMJ, The</i> , 2016, 352, i1345.	6.0	0
161	Fish Oils and Bleedingâ€”Where Is the Evidence?â€”Reply. <i>JAMA Internal Medicine</i> , 2016, 176, 1406.	5.1	0
162	Author reply to Letter to Editor â€œWeaning outcome of solid cancer patients requiring mechanical ventilation in the ICU: Other factors to exploreâ€• <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1678-1679.	1.7	0

#	ARTICLE	IF	CITATIONS
163	A More Balanced Approach to Dietary Supplement Data—Reply. <i>JAMA Pediatrics</i> , 2019, 173, 104.	6.2	0
164	Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 916.	5.1	0
165	Opioid use disorder during pregnancy: long-term developmental outcomes. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 1016-1016.	2.1	0
166	Reply to: The informed majority could help make research into Alzheimer's disease fairer and more efficient. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1883-1885.	2.6	0
167	Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. <i>JAMA Network Open</i> , 2022, 5, e221117.	5.9	0